target="_blank">Food and Drug Administration (FDA), includes guidelines such as the 21 CFR Part 11 regarding electronic records, as well as the FDA’s Digital Health Innovation Action Plan, which encompasses software as a medical device (SaMD) and mobile medical applications.

Documentation

As the integration of digital biomarkers and mHealth continues to grow, the specifics of what should be included in regulatory submissions have garnered significant attention. RA teams are tasked with ensuring compliance and facilitating the acceptance of digital health technologies through rigorous documentation practices that encompass:

1. Clinical Evaluation Reports (CERs): Documenting the clinical safety and performance of digital health products must reflect the evolving role of real-world data. This includes justifying any bridging studies necessary for applications lacking traditional clinical trials.
2. Risk Management Plans (RMPs): Digital health products require specific risk management strategies that identify and mitigate risks associated with software use and data privacy. This is essential for maintaining compliance with regulatory expectations across different jurisdictions.
3. Pharmacovigilance Plans: The incorporation of digital biomarkers necessitates robust pharmacovigilance strategies, including definitions of adverse events and clear algorithms for monitoring real-world safety signals.

Review/Approval Flow

The approval process for digital health products differs from traditional pharmaceuticals. It operates within a framework that prioritizes iterative reviews and adaptive regulations. Key decision points in this flow include:

1. Pre-Submission Meetings: In the FDA’s framework, pre-submission meetings are recommended to facilitate discussions regarding the digital strategy, deployment of digital biomarkers, and potential regulatory pathways.
2. Determining Classification: RA professionals must decide if the product will be classified as a medical device, and whether it fits under existing regulations or if a new framework needs to be established. This might include classifying products differently in the EU versus the US.
3. Post-Market Surveillance: Continuous monitoring is paramount. A Solid pharmacovigilance plan for post-market surveillance is needed to ensure compliance with both FDA and EMA requirements to capture real-world evidence using digital tools.

Common Deficiencies

With the burgeoning integration of digital therapies and biomarker technologies in submissions, common deficiencies frequently arise. Notable issues often questioned by regulatory agencies include:

• Lack of Clear RWE Utilization: Submissions that do not adequately justify the use of real-world evidence can lead to significant delays. RA teams must define how real-world data informs product safety and effectiveness.
• Inadequate Risk Assessment: Insufficient risk assessments focusing on digital aspects of products often lead to non-compliance findings. This includes considerations of cybersecurity risks associated with mobile apps.
• Non-Alignment with Pharmacovigilance Standards: Many submissions fail to detail how pharmacovigilance activities will be updated to incorporate digital data. RA professionals should ensure all methodologies align with ICH E2E pharmacovigilance guidelines.

RA-Specific Decision Points

Variation vs. New Application

One pivotal decision point for RA teams is determining whether changes to a product (for instance, incorporating an AI digital health solution) require a variation to an existing application or the submission of a new application. The following considerations should guide this decision:

• If the integration of digital health capabilities significantly alters the product’s intended use or mechanism of action, a new application is warranted.
• If the updates primarily enhance functionalities or efficiencies without fundamentally changing clinical outcomes, a variation can be pursued.

Justifying Bridging Data

In circumstances where clinical evidence is derived from studies leveraging digital biomarker data, justifying the reliance on this data for regulatory submissions is vital. Teams should focus on:

• Conducting preclinical evaluations that validate the use of digital biomarkers, demonstrating their relevance to traditional endpoints.
• Clearly articulating the rationale for utilizing bridging studies, ensuring that they are designed to ascertain similar efficacy outcomes and safety profiles expected from traditional clinical trials.

Interaction with CMC, Clinical, PV, QA, and Commercial Teams

RA professionals must actively collaborate with various cross-functional teams to ensure compliance is maintained throughout the product lifecycle:

• CMC (Chemistry, Manufacturing and Controls): Collaboration ensures that product quality is maintained as digital capabilities are introduced, especially regarding any software embedded in the manufacturing process.
• Clinical: RA must liaise with clinical teams to align on trial protocols, ensuring that the implementation of digital biomarkers complements traditional methodologies.
• Pharmacovigilance: Working closely with pharmacovigilance teams is crucial for maintaining safety monitoring practices as digital health data collection becomes standard.
• Quality Assurance (QA): Regulatory compliance must be supported by a robust QA framework that encompasses the assessment and validation of digital health tools.
• Commercial: Regulatory insights are critical for commercial operations, particularly when navigating the complex promotional landscape for digital health products.

Conclusion

As digital health innovations continue reshaping the pharmaceutical landscape, Regulatory Affairs teams are positioned at the intersection of technology and compliance. Understanding relevant regulations, documentation practices, and agency expectations is essential for guiding the successful integration of digital biomarkers and mobile health technologies into regulatory strategies. By adhering to best practices and fostering cross-functional collaboration, RA professionals can navigate this new regulatory terrain and contribute to a more responsive and adaptive healthcare landscape.